Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. SPY
7. CVS
8. UNH
9. SBUX
10. AXP

Go back to Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022

February 2, 2023 6:59 AM EST

Reports Fourth Quarter Revenues of $11.4 Billion; Full-Year Revenues of $46.2 Billion Fourth Quarter Revenues from In-Line Products and New Product Portfolio were $9.0 Billion, an Increase of 7%, or 12% When Adjusted for Foreign Exchange Full-Year Revenues from In-Line Products and New Product Portfolio were $35.4 Billion, an Increase of 9%, or 13% When Adjusted for Foreign Exchange Posts Fourth Quarter GAAP EPS of $0.95 and Non-GAAP EPS of $1.82; Includes Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing... More